Search alternatives:
tibi development » iii development, vii development, viii development
wbi development » bi development, wai development, i development

1
Published 2018
Canadian Agency for Drugs and Technologies in Health
..., and generally do not survive past two years of age due to respiratory failure. Patients with SMA type II achieve...

2
Published 2018
Canadian Agency for Drugs and Technologies in Health
..., and generally do not survive past two years of age due to respiratory failure. Patients with SMA type II achieve...

3
Published 2011
Canadian Agency for Drugs and Technologies in Health

4
Published 2016
Canadian Agency for Drugs and Technologies in Health

5
Published 2016
Canadian Agency for Drugs and Technologies in Health

8
Published 2016
Canadian Agency for Drugs and Technologies in Health
... increased by 89% from 2004 to 2013, rising from 2.8 to 5.3 per 1000 live births. This suggests a possible...

9
Published 2016
Canadian Agency for Drugs and Technologies in Health
... increased by 89% from 2004 to 2013, rising from 2.8 to 5.3 per 1000 live births. This suggests a possible...

10
Published 2017
Canadian Agency for Drugs and Technologies in Health
... to these cancers were predicted for 2011.2 AK typically manifests as 2 mm to 6 mm scaly macules, papules...

11
Published 2017
Canadian Agency for Drugs and Technologies in Health
... to these cancers were predicted for 2011.2 AK typically manifests as 2 mm to 6 mm scaly macules, papules...

12
by Foerster, Vicki, Perras, Christine, Spry, Carolyn, Weeks, Laura Christine
Published 2015
Canadian Agency for Drugs and Technologies in Health
... to increase population immunization coverage. The objective of this study is to inform the development of a...

13
by Foerster, Vicki, Perras, Christine, Spry, Carolyn, Weeks, Laura Christine
Published 2015
Canadian Agency for Drugs and Technologies in Health
... to increase population immunization coverage. The objective of this study is to inform the development of a...

14
Published 2017
Canadian Agency for Drugs and Technologies in Health
... patients with New York Heart Association (NYHA) functional class II or III HF who are in sinus rhythm...

15
Published 2017
Canadian Agency for Drugs and Technologies in Health
... patients with New York Heart Association (NYHA) functional class II or III HF who are in sinus rhythm...

16
Published 2014
Canadian Agency for Drugs and Technologies in Health
...Recent advances in genomic sequencing and bioinformatics have led to development of noninvasive...

17
Published 2014
Canadian Agency for Drugs and Technologies in Health
...Recent advances in genomic sequencing and bioinformatics have led to development of noninvasive...

18
Published 2021
Canadian Agency for Drugs and Technologies in Health

19
Published 2016
Canadian Agency for Drugs and Technologies in Health
... for the symptomatic relief of chronic pain has also been studied....

20
Published 2016
Canadian Agency for Drugs and Technologies in Health
... for the symptomatic relief of chronic pain has also been studied....